Company Overview and News

 
When Even Value Investors Can't Find Any - Bloomberg Gadfly

2017-12-08 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
Fund Manager's Update Q1 2017

2017-05-25 londonstockexchange
Terra Capital Plc. ('TCA' or the 'Fund'), the AIM quoted investment company focused on investing in value opportunities globally, primarily in frontier markets is pleased to report that it has received the latest report from Terra Partners Asset Management Limited ('TPAM' or the 'Fund Manager'), covering its activities in Q1 2017.

 
China Blood Product Industry Report 2017: Product Market Size Expected to Hit RMB47.5 Billion in 2021 - Research and Markets

2017-05-17 prnewswire
Research and Markets has announced the addition of the "China Blood Product Industry Report, 2017-2021" report to their offering.

 
Research and Markets - China Truck Industry Report, 2017-2021: 17 Truck Manufacturers Including FAW Group, Dongfeng Motor, Sinotruk, Beiqi Foton Motor, and Jiangling Motors Co.

2017-05-16 prnewswire
Research and Markets has announced the addition of the "China Truck Industry Report, 2017-2021" report to their offering.

 
China Cold Chain Logistics Industry Report, 2016-2020

2016-03-23 prnewswire
NEW YORK, March 23, 2016 /PRNewswire/ -- With the growth of China's economy over the past decade, the residents' food consumption structure has experienced constant adjustment, a situation that led to a rising demand for food cold chain. Moreover, the government at all levels has poured more funds into the construction of cold-chain infrastructure in an attempt to spur the rapid development of cold chain logistics.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...